Candesartan cilexetil in hypertension: Effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin- aldosterone system

Blood Pressure

Volumn 8, Issue 4, 1999, Pages 242-247

  Fridman, Katarina U B ^a,b   Wysocki, Marian ^a   Friberg, Peter R ^a   Andersson, Ove K ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin II receptor blocker; Baroreceptor sensitivity; Candesartan cilexetil; Haemodynamics; Hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CATECHOLAMINE; RENIN;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FOREARM BLOOD FLOW; HEMODYNAMICS; HUMAN; PLASMA RENIN ACTIVITY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATATION;

EID: 0033390756     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599439634     Document Type: Article

References (23)

1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1992; 62: 377-99.
2. Julius S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol 1991; 67: 3B-7B.
3. Lund-Johansen P, Omvik P. Cardiac effects of ACE inhibition. J Cardiovasc Pharmacol 1993; 22(Suppl 1): S36-40.
4. Heesch CM, Crandall ME, Turbek JA. Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow. Am J Physiol 1996; 270: R728-37.
5. Mancia G, Parati G, Pomidossi G, et al. Modification of arterial baroreflexes by captopril in essential hypertension. Am J Cardiol 1982; 49: 1415-9.
6. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45: 205-51.
7. Fridman K Andersson IK, Wysocki M, Friberg P. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients. Eur J Clin Pharmacol 1998; 54: 497-501.
8. Messerli F, Weber M, Brunner H. Angiotensin II receptor inhibition. Arch Intern Med 1996; 156: 1957-65.
9. Rongen GA, Brooks SC, Ando S, Dajani HR, Abramson BL, Floras JS. Neural and hypotensive effects of angiotensin II receptor blockade. Hypertension 1998; 31: 378-83.
10. 1 receptor. Eur J Pharmacol 1997; 319: 13-46.
11. Shibouta Y, Inada Y, Ojima M, et al. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2-2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1Hbenzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexylcarbonyloxy)-ethyl-2-ethoxy-1 -[[2′-(1H-tetrazol-5-yl)-piphenyl-4-yl]-methyl-1-benzimidazole-7- carboxylate (TCV-116). J Pharmacol Exp Ther 1993; 266: 114-20.
12. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11(Suppl 2): S49-53.
13. Andersson OK, Berglund G, Hansson L, et al. Organisation and efficacy of an outpatient clinic. Acta Med Scand 1978; 203: 391-8.
14. Nilsson NJ. A linearly responding dichromatic cuvette densitometer for dye-dilution curves. Scand J Lab Invest 1963; 69(Suppl): 181-93.
15. Whitney RJ. The measurement of volume change in human limbs. J Physiol 1953; 121: 1-27.
16. Gribbin B, Pickering TG, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971; 29: 424-31.
17. Morton JJ, Webb DJ. Measurement of plasma angiotensin [Letter]. Clin Sci 1985; 68: 483-4.
18. Giese J, Jörgensen M, Damkjaer-Nielsen M, Lund JO, Munck O. Plasma renin concentration measured by the use of radioimmunoassay. Scand J Clin Lab Invest 1970; 26: 355-67.
19. Malvano R, Benedetto S, Galbiati A, Gandolfi C, Grosso P, Rolleri E. Recent trends in methodological simplification of steroid radioimmunoassay. Horm Res 1978; 9: 422-39.
20. Kaplan LA. Catecholamines - plasma. In: Pesce AJ, Kaplan LA, editors. Methods in clinical chemistry. Toronto: Mosby, 1987: 944-8.
21. Cockcroft JR, Sciberras DG, Goldberg MR, et al. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonist in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579-84.
22. Baan J Jr, Chang PC, Vermeij P, Pfaffendorf M, van Zwieten PA. Venoconstriction by angiotensin II in the human forearm is inhibited by losartan but not by nicardipine. J Cardiovasc Pharmacol 1998; 31: 50-5.
23. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-78.